RE:RE:RE:RE:RE:RE:Q3 The increase in R&D in Q3 over the average of the last 4 quarters was about $742k, which turns out to be about 92% of entire Q3 loss. So, it seems that, without this extra R&D expense, the company was dangerously close to breaking even this quarter. I would like Lisa to comment more on the one time FHIR expense located in R&D - the reason for it but more importantly the amount of it.
Regardless, with A/R collections being (hopefully) soon normalized, continued revenue growth and nicely controlled expenses, the company is very close to being completely de-risked. While I would have liked revenue to have been slightly higher, overall the company is making further progress.
Actually, if you take out some R&D, the expenses seem incredibly well controlled. Kudos to Reliq on that alone.